Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed monthly ranibizumab dosing for subretinal fluid with persistent RPE detachment in neovascular AMD
KCT0002804Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in age-related macular degeneration (AMD), sponsored by Novartis. Started Mar 2016; status: active, not recruiting.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on KCT0002804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0002804.